News / 12 Jul 2021
Summit Therapeutics Presents Breakthrough Research Data from Ph II Studies, including Evidence Validating Microbiome Preservation, Potential Benefit for the Control of Antimicrobial Resistance, and a Novel Mechanism of Action, for its Investigational Drug Ridinilazole
News / 01 Jul 2021
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
News / 08 Jun 2021
Summit Therapeutics set to join Russell 3000® Index
We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.
Chairman & Chief Executive Officer